Harvard Health Blog
Combination hormonal therapy boosts survival in men with aggressive prostate cancer
By: Charlie Schmidt, Editor, Harvard Medical School Annual Report on Prostate Disease A standard approach for treating aggressive prostate cancer is to give therapies that block testosterone, a tumor-stimulating hormone. Should initial hormonal therapies fail, doctors can switch to other drugs that suppress testosterone in different ways. One of them, a drug called abiraterone, has been shown to significantly extend lifespans in men who have become resistant to other hormonal treatments.